What’s next for hot biotech stock Viking Therapeutics? Here’s how the company can scale up.
Viking has long been viewed as a takeover target, given the positive data from early VK2735 trials. The company’s most recent ...
What's next for Viking Therapeutics? Here's how the company can scale up.
Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...
Daily6 天
No Impact of HFNC Flow Rate on Reintubation or NIV Use in Post-Extubation Patients, shows ...
The findings were published online in the CHEST Journal on December 30, 2024.